✦ LIBER ✦

Sa.98. Preclinical and Clinical Development of a Second Generation Peptide Copolymer for the Treatment of Multiple Sclerosis

✍ Scribed by Joseph Kovalchin; Jeffrey Krieger; Ingrid Dufour; Kathy Collins; Michelle Genova; Michael Augustyniak; Kristen Rafuse; Alain Patat; Uday Patel; Edward Mascioli; Eric Zanelli

Book ID: 113540460
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 55 KB
Volume: 127
Category: Article
ISSN: 1090-2341
DOI: 10.1016/j.clim.2008.03.319

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effect of vesnarinone on TNFα produc

The effect of vesnarinone on TNFα production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis

✍ H Jiang; B Bielekova; H Okazaki; K Clarence-Smith; K.P Johnson; G Bergey; R Mart 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 679 KB

ArifloTM(SB 207499), a Second Generation

ArifloTM(SB 207499), a Second Generation Phosphodiesterase 4 Inhibitor for the Treatment of Asthma and COPD: from Concept to Clinic

✍ T.J. Torphy; M.S. Barnette; D.C. Underwood; D.E. Griswold; S.B. Christensen; R.D 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 104 KB

Preclinical pharmacokinetics of MFGR1877

Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma

✍ Amrita V. Kamath; Dan Lu; Priyanka Gupta; Denise Jin; Yan Xin; Ann Brady; Jean-P 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 426 KB

O114. Pre-clinical development of a bi-f

O114. Pre-clinical development of a bi-functional, cancer cell homing, PKCe inhibitory peptide for the treatment of head and neck cancer

✍ Bao, L.W.; Gorin, M.A.; Merajver, S.D.; Teknos, T.N.; Pan, Q. 📂 Article 📅 2009 🏛 Elsevier Science ⚖ 42 KB

[RSC Drug Discovery] New Therapeutic Str

[RSC Drug Discovery] New Therapeutic Strategies for Type 2 Diabetes Volume 74 || Chapter 11. The Discovery and Development of MB07803, a Second-Generation Fructose-1,6-bisphosphatase Inhibitor with Improved Pharmacokinetic Properties, as a Potential Treatment of Type 2 Diabetes

✍ Jones, Rob M 📂 Article 📅 2012 🏛 Royal Society of Chemistry ⚖ 720 KB